OpenBilldrug price receipt

NADAC week of 2026-10-14

RASUVO 17.5 MG/0.35 ML AUTOINJ

FDA nonproprietary name: methotrexate

For 1.4 mL

Pharmacies pay

$573.90 filed

1.4 × $409.92919 per ML

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-04-01 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D paid

$513.88 filed

1.4 × $367.06071 per ML, Part D average

Medicare's price is not your price.

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18


The spread

0.90× estimated

Medicare paid 10% less than pharmacies pay.

Part D averages every strength and form sold under “Rasuvo” / “Methotrexate/PF” into one figure, so it is not specific to this NDC.

OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-04-01 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)

Cost-plus estimate

$664.99 estimated

$573.90 + $86.09 (15%) + $5.00 fee per fill = $664.99

This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out

OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-04-01 (file of 2026-10-14, retrieved 2026-10-17)

Open the interactive card Change the quantity, type what you were charged, and see every record in full.

What it is

RASUVO 17.5 MG/0.35 ML AUTOINJ is how the CMS NADAC file names this product. The FDA NDC Directory lists it as methotrexate, under the trade name “Rasuvo”.

FDA gives its dosage form as injection, solution and its route as subcutaneous.

The labeler, the company named on the label, is Medexus Pharma Inc.

FDA’s Established Pharmacologic Class for it is Folate Analog Metabolic Inhibitor.

The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 59137-0525-04.

NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $573.90 for 1.4 mL (1.4 × $409.92919 per ML, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-04-01. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation codes for it: 4, carried forward from the previous file; 5, calculated based on package size.

This NDC’s NADAC was carried forward from an earlier file (NADAC explanation code 2 or 4), not newly surveyed: it took effect on 2026-04-01. The file is new; the price is not.

The NDC

Other strengths, forms and brands

13 other products in the NADAC file share the FDA nonproprietary name methotrexate with RASUVO 17.5 MG/0.35 ML AUTOINJ.

ProductPharmacies pay per unitMedicare per unit
METHOTREXATE 2.5 MG TABLET
generic · tablet
$0.15774 per EA filed
eff. 2026-09-23
$0.157 per EA derived
Part B limit 2026 Q4
METHOTREXATE 50 MG/2 ML VIAL
generic · solution / injection, solution / injection
$1.23696 to $3.1832 per ML filed
eff. 2026-09-23
$1.4545 per ML derived
Part B limit 2026 Q4
METHOTREXATE 250 MG/10 ML VIAL
generic · injection, solution / injection
$0.702 to $3.1832 per ML filed
eff. 2026-09-23
$1.4545 per ML derived
Part B limit 2026 Q4
RASUVO 7.5 MG/0.15 ML AUTOINJ
brand · injection, solution
$960.29324 per ML filed
eff. 2026-04-01
$367.06071 per ML filed
Part D 2024 average
RASUVO 10 MG/0.2 ML AUTOINJ
brand · injection, solution
$721.8144 per ML filed
eff. 2026-04-01
$367.06071 per ML filed
Part D 2024 average
RASUVO 12.5 MG/0.25 ML AUTOINJ
brand · injection, solution
$574.86795 per ML filed
eff. 2026-04-01
$367.06071 per ML filed
Part D 2024 average
RASUVO 15 MG/0.3 ML AUTOINJ
brand · injection, solution
$480.00227 per ML filed
eff. 2026-09-23
$367.06071 per ML filed
Part D 2024 average
RASUVO 17.5 MG/0.35 ML AUTOINJ this page
brand · injection, solution
$409.92919 per ML filed
eff. 2026-04-01
$367.06071 per ML filed
Part D 2024 average
RASUVO 20 MG/0.4 ML AUTOINJ
brand · injection, solution
$362.2851 per ML filed
eff. 2026-09-23
$367.06071 per ML filed
Part D 2024 average
RASUVO 25 MG/0.5 ML AUTOINJ
brand · injection, solution
$289.365 per ML filed
eff. 2026-09-23
$367.06071 per ML filed
Part D 2024 average
TREXALL 5 MG TABLET
brand · tablet, film coated
$24.08844 per EA filed
eff. 2026-01-01
$41.73652 per EA filed
Part D 2024 average
TREXALL 7.5 MG TABLET
brand · tablet, film coated
$36.20914 per EA filed
eff. 2026-02-18
$41.73652 per EA filed
Part D 2024 average
TREXALL 10 MG TABLET
brand · tablet, film coated
$48.13525 per EA filed
eff. 2026-09-23
$41.73652 per EA filed
Part D 2024 average
XATMEP 2.5 MG/ML ORAL SOLUTION
brand · solution
$21.76353 per ML filed
eff. 2026-09-23
$19.76312 per ML filed
Part D 2024 average

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. between 2026-01-01 and 2026-09-23 (4 dates) · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

OpenBill calculation · october-2026-medicare-part-b-payment-limit-files-final.zip + october-2026-ndc-hcpcs-crosswalk-final.zip · Part B limit 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18) · Part B crosswalk 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18)

Compared with its class

Its NADAC price is $409.92919 per ML filed.

Of the 9 other products in FDA’s Folate Analog Metabolic Inhibitor class priced per ML, 4 have a higher middle NADAC price and 5 a lower one. The one in the middle is RASUVO 20 MG/0.4 ML AUTOINJ, at $362.2851 per ML filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-04-01, 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

What Medicare paid

Medicare Part D paid $513.88 for 1.4 mL, at an average of $367.06071 per ML in 2024 (2024-01-01 to 2024-12-31) for “Rasuvo” and “Methotrexate/PF”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 31,894 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

Questions

Why is the comparison with Medicare for RASUVO 17.5 MG/0.35 ML AUTOINJ labelled estimated?
Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Rasuvo / Methotrexate/PF: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's ML. Joined on brand name.
Why does this page start at 1.4 mL?
NADAC prices this product per ML. The FDA NDC Directory’s package description gives 1.4 mL in one package for this product’s NDC (“4 PACKAGE in 1 CARTON (59137-525-04) / .35 mL in 1 PACKAGE (59137-525-00)”), so the card starts at one package: 1.4 ML. Change it to match your prescription.